Abstract
Objective: Semaglutide, a GLP1 receptor agonist for diabetes mellitus, has been reported to not only improve blood glucose and body weight, but also to lower blood pressure. In this study, we investigated the effects of oral semaglutide on blood pressure. Methods: We compared blood pressure, body weight, and HbA1c before, one month after, and three months after semaglutide administration in patients with type 2 diabetes mellitus attending the first author's outpatient clinic who were started on the oral formulation of semaglutide. We selected the patients for study who were administrated oral semaglutide formulations as new additions to previous therapy or conversions from other oral diabetes medications, and those converted from injectable GLP1 receptor agonists were excluded. Results: Baseline clinical characteristics of the subjects were 12 (10 men, 2 women), age 57.9 ± 9.8 years, weight 94.9 ± 16.1 kg, blood pressure 147.9 ± 14.3/84.3 ± 6.0 mmHg, HbA1c 7.4 ± 0.6%. Systolic blood pressure was 138.5 ± 11.8 mmHg for 1 month after treatment and 136.6 ± 9.3 mmHg for 3 months after treatment, showing a significant decrease compared to before treatment (p < 0.05). On the other hand, HbA1c and body weight significantly decreased (p < 0.05) to 6.9 ± 0.9% and 92.2 ± 16.6 kg, respectively, after 3 months of treatment, but no significant change was observed after 1 month of treatment. No significant correlation was observed among the changes in HbA1c and body weight and systolic blood pressure at 1 and 3 months. Conclusions: Significant reductions in HbA1c, body weight, and systolic blood pressure were observed with the oral formulation of the GLP1 receptor agonist semaglutide. The decrease in systolic blood pressure was preceded by a decrease in HbA1c and body weight.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
